Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
Akiyama S, Yokoyama K, Yagi S, Shinzaki S, Tsuruta K, Yoshioka S, Sako M, Shimizu H, Kobayashi M, Sakurai T, Nomura K, Shibuya T, Takahara M, Hiraoka S, Sugai K, Yanai S, Yoshida A, Koroku M, Omori T, Saruta M, Matsumoto T, Okamoto R, Tsuchiya K, Fujii T.
Akiyama S, et al. Among authors: shimizu h.
Aliment Pharmacol Ther. 2024 Mar 17. doi: 10.1111/apt.17961. Online ahead of print.
Aliment Pharmacol Ther. 2024.
PMID: 38494867
BACKGROUND AND AIMS: While filgotinib, an oral Janus kinase (JAK) 1 preferential inhibitor, is approved for moderately to severely active ulcerative colitis (UC), real-world studies assessing its short- and long-term efficacy and safety are limited. METHODS: This is a mult …
BACKGROUND AND AIMS: While filgotinib, an oral Janus kinase (JAK) 1 preferential inhibitor, is approved for moderately to severely active ul …